30 March -1 April 2020 | Business Design Centre London
2000+
Attendees
700+
1-2-1 Meetings
300+
Speakers
100+
Exhibitors
12
Streams
2020 KEY SPEAKERS
Gene Editing
GENE EDITING, Tuesday 31 March 2020
CONFERENCE DAY 1 - TUESDAY 31st March 2020
Opening Keynotes Day 1 – CAR-T & Immunotherapy focus
09:00
Keynote presentaton: Autologous Mesothelin-targeting CAR-T to tackle solid tumours in the clinic
- The presentation will highlight results to date of mesothelin-targeted CAR T-cell clinical trial results
- Advances in preclinical research of CAR T-cell therapy for solid tumors will be presented
- Novel strategies for overcoming hurdles to solid tumor CAR T-cell therapy will be discussed
09:20
Realizing the promise of ATMPs for patients around the world
- Working with regulators to navigate scale up challenges in manufacturing
- Strategies in supply chain and patient delivery
- Tackling post manufacturing commercialization challenges such as pricing and finding highly skilled experts
- Durability
10:20
Morning Coffee Break
11:40
Effective Integration Strategies Through a Compliance Unified Ecosystem (CUE)
- Systems Integration continues to be a major issue in the production and distribution of Advanced Therapies
- Well-defined strategies for the integration of independent informatics platforms will be critical for future standardization and workflow optimization
- Cryoport’s Compliance Unified Ecosystem (CUE) is driving standard practices for systems integration in the industry
12:00
Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for you
Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for your table number to participate.
1. Raw material supply for the commercial manufacturing of cell and gene therapies
Frank Hecht, Vice President Marketing And Sales, CellGenix GmbH
11. Cord blood as a source of new cells
12. Tissue engineering for organ regeneration
Vaidehi Joshi, Scientist II, Therapeutics, Organovo
13. TBC
14. Making allogeneic cell therapy a reality
Devyn Smith, Chief Operating Officer And Head Of Strategy, Sigilon
15. Industry-no profit alliances: how to optimize synergies
Elena Beltrami, Business Development Manager, Fondazione Telethon
17. How companies can interact with the regulator and various pitfalls to be aware of
John Johnston, Clinical Assessor, Medicines & Healthcare Products Regulatory Agency
18. Ensuring ATMP access to patients
Delphine Roulland, Director Government Affairs And Public Policy, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
19. Roundtable available
2. Physiological conditions and analytical and monitoring tools for 3D cell cultivations
Cornelia Kasper, Professor, Biopharmaceutical Production And Technology, B.O.K.U.
20. Tackling solid tumours in the clinic
21. Neurological applications for ATMPs
22. Development of regenerative medicines for cardiovascular indications
23. Renal applications for ATMPs
24. Tackling diabetes with ATMPs
4. Automation and continuous manufacture
Lior Raviv, Vice President Of Development, Pluristem Therapeutics
5. Considerations for manufacture scale-up from academia to commercial manufacturing
Johannes Van Der Loo, Clinical Vector Core Director, The Children's Hospital of Philadelphia
6. Defining standards for gene therapy
Dawn Henke, Senior Technical Program Manager, Standards Coordinating Body
7. Mechanisms of MSC action and potency assays
Mary Murphy, Principle Investigator, Remedi National University of Ireland Galway
9. Exploring the crossover between human and veterinary applications for stem cells
Joanna Miller, Chief Scientific Officer, Cell Therapy Sciences
13:00
Lunch
GENE EDITING
14:20Directed evolution of novel aden-associated viral vectors for clinical gene therapy
- Adeno-associated viral vectors are increasingly succeeding in the clinic, leading to several regulatory approvals
- Vectors based on natural versions of AAV suffer from numerous shortcomings, requiring high dosages, invasive routes of administration, and/or limited efficacy for many targets
- Our directed evolution approach involves high throughput selection of highly optimized AAVs from a library of a billion variants
GENE EDITING
15:00The promise of advanced therapies for 21st Century Medicines
- Novartis is re-imagining how we treat and care for patients: Innovative platforms for Advanced Therapies
- Genome editing technologies with a focus on CRISPR/Cas9: Opportunities and challenges of CRISPR as therapeutic modality
- Genome editing clinical trials: Current status
GENE EDITING
15:40CRISPR off-targets: how to detect and avoid them
GENE EDITING
16:00Development of therapeutic genome editing strategies
Seokjoong Kim, Executive Director Of R&D And Strategic Alliances, ToolGen
16:20
Afternoon Break
GENE EDITING
17:00Targeted Elimination of viral DNA using ARCUS gene editing
18:00
Close of Conference for the day - Please join us for an evening drinks reception at the iconic Emirates Stadium
last published: 28/Jan/20 14:05
GENE EDITING, Wednesday 1 April 2020
08:55
Opening Remarks
09:00
Gene therapy 2.0: New clinical data, therapeutic applications and next generation technologies
- Latest updates on LUXTURNA studies to treat blindness, haemophilia and rare disease
- Tackling the challenges of viral gene therapies i.e. immunogenicity
- Developing the next generation of gene therapies, what does the future hold?
09:20
Next-generation gene editing technology for allogeneic immune cell therapeutics
- Next-generation CRISPR-Cas9 technology
- Significantly enhanced editing specificity
- Editing in immune cells for generation of functionally tuned therapeutics
09:40
Repairing the human genome with designed zinc finger editing reagents
- Overview of Sangamo’s zinc finger protein gene editing technology, including new innovations that facilitate specificity, precision, and gene editing efficiency
- Will address specific examples of defined therapeutic applications including the generation of reagents suitable for use in tauopathies, Huntington’s disease, and lysosomal storage diseases
10:00
In vivo gene editing paediatric patients with rare diseases
10:20
Networking Refreshments
13:00
Neworking Lunch
GENE EDITING
14:40Analytical development in gene editing
- Current trends and challenges for analytical development in gene editing
- Delivery vehicle characterization: viral and non-viral
- Characterization of cargo: new modalities
Bo Yan, Senior Scientist, Analytical Development, Beam Therapeutics
16:20
Networking refreshments
GENE EDITING
17:40mRNA characterization
GENE EDITING
18:00Closing panel discussion
Bo Yan, Senior Scientist, Analytical Development, Beam Therapeutics
last published: 28/Jan/20 14:05
Organiser
